(12) United States Patent (10) Patent No.: US 8,771,972 B2 Salamone Et Al
US00877 1972B2 (12) United States Patent (10) Patent No.: US 8,771,972 B2 SalamOne et al. (45) Date of Patent: Jul. 8, 2014 (54) CLOZAPINE IMMUNOASSAY (56) References Cited (75) Inventors: Salvatore J. Salamone, Stockton, NJ U.S. PATENT DOCUMENTS (US); Jodi Blake Courtney, 6, 197,764 B1 3/2001 Bradley et al. Doylestown, PA (US); Howard Sard, 2006/02231.34 A1* 10, 2006 Salamone et al. ........... 435,792 Arlington, MA (US); Christopher 2006/0252744 A1 11/2006 Burstein Spedaliere, Allentown, PA (US) 2009, 0215082 A1 8/2009 Salamone et al. 2012/030 1973 A1* 11/2012 Salamone et al. ............ 436,501 (73) Assignee: Saladax Biomedical Inc., Bethlehem, OTHER PUBLICATIONS PA (US) Ming et al., “Therapeutic drug monitoring of clozapine and (*) Notice: Subject to any disclaimer, the term of this norclozapine in human serum using ultra-performance liquid chro patent is extended or adjusted under 35 matography-tandem mass spectrometry.” J. Anal. Toxicol., 2009, vol. U.S.C. 154(b) by 189 days. 33, No. 4, pp. 198-203.* Mendoza et al., “N-Desmethylclozapine: Is There Evidence for its Antipsychotic Potential?.” Clin. Neuropharm., 2009, vol. 32, issue 3, (21) Appl. No.: 13/186,147 pp. 154-157.* Gardner et al., “A Comparison of the Covalent Binding of Clozapine (22) Filed: Jul.19, 2011 and Olanzapine to Human Neutrophils. In Vitro and In Vivo.” Mol. Pharmacol., 1998, vol. 53, pp. 999-1008.* (65) Prior Publication Data Liu et al., "Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells,” J. Pharm. US 2012/O3O1974 A1 Nov.
[Show full text]